SOLICITATION NOTICE
68 -- Immunophenotyping Reagents
- Notice Date
- 8/19/2002
- Notice Type
- Solicitation Notice
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Research Contracts Br., 6120 Executive Blvd. EPS Suite 600, Rockville, MD, 20852
- ZIP Code
- 20852
- Solicitation Number
- NCI-20111-NG
- Response Due
- 9/3/2002
- Point of Contact
- Malinda Holdcraft, Purchasing Agent, Phone (301) 402-4509, Fax (301) 402-4513, - Caren Rasmussen, Lead Contract Specialist, Phone (301) 402-4509, Fax (301) 402-4513,
- E-Mail Address
-
holdcram@exchange.nih.gov, cr214i@nih.gov
- Description
- The National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Pathology (LP), Flow Cytometry Unit (FCU) plans to enter into a sole source contract with Beckman Coulter, 8920 Route 108, Columbia, Maryland 21045, for cost per test for immunophenotyping reagents. The supplies and services herein are commercial as defined in FAR Part 12, and this acquisition is being made in accordance with the test program for using simplified procedures for certain commercial items as authorized in FAR Part 13.5. The North American Industry Classification System code is 422210 and the business size standard is 100 employees. Part I. Reagents. The Laboratory of Pathology (LP), Flow Cytometry Unit (FCU) requires a more proficient mechanism for the preparation of biological materials and other fluids for flow cytometric immunophenotyping. Currently the laboratory performs tests manually. This requires 100% concentration and is laborious and time consuming as well as being a major focus of laboratory errors. The laboratory receives more requests for their services than they can perform with current personnel and technology. Specimens are being sent out at great expense to NCI protocols. Currently the reagents being used are; CD3 PC5, Flow Check Fluorospheres, Flow-Set Fluorospheres, Whole blood lyse kit 300T, Isoflow, Coulter CLENZ, CD10 PC5, and CD5 PC5 reagents. The laboratory currently has a Government owned flow cytometer to aid in the preparation of these immunophenotyping tests. Therefore, the need for reagent supplies to operate the existing flow cytometer and to produce more tests, the use of a new flow cytometer stainer and laser are required. The laboratory currently tests approximately 900 specimens annually, setting up anywhere from 1-22 4 color tubes (4 different antibodies in each tube). With a 10 tube panel, 40 different antibodies in may combinations. Minimum Requirements: REAGENTS; Antibodies and other supplies must be of high quality and are extensively tested prior to use in the laboratory. The antibodies must be of; 1) a particular clone type, 2) specificity and; 3) have a low antibody to fluorochrome ratio. These particular antibodies/clones are used as therapeutics in our patient protocols. Other reagents are fine with normal cells but fail to react with malignant cells and would fail to find tumor if they were used. Therefore, each clone is tested and compared to certain standards. Part II: As a result of the cost per test, NCI will receive use of a Robotic sampler which will allow the FCU to (1) provide accurate flow cytometric immunophenotyping service in the diagnostic evaluation of Clinical Center patients for hematopoietic neoplasia; (2) instruct residents and fellows in interpretation of clinical flow cytometric immunophenotypic results; and (3) plan and conduct research on human and animal diseases. Minimum Requirements: Equipment; 1) robotic pipetting and RBC lysing system, 2) allow precise, accurate and timely measured aliquots of expensive reagents to be pipetted into multiple tubes. Presently these antibodies are measured by hand creating documented multiple problems with inappropriately measured and pipetted tubes. 3) allows for simultaneous analysis of multiple complex parameters so that cell size, granularity, DNA content, viability (including the presence of apoptotic cells), cell kinetics, apoptotic markers and the presence of multiple intracellular and surface proteins can be determined for each cell in a sample studied, 4) data produced is both quantitative and objective, thus reducing bias in diagnostic evaluation. This highly sensitive technique, coupled with the ability to rapidly analyze multiple parameters in large numbers of cells, allows the detection of small sub-populations of neoplastic cells. Flow cytometry is a sensitive technique for the analysis of benign and malignant tumors. The results of minimal residual disease detection can in some disease processes surpass molecular testing (sensitivities of one in ten to the third [1in 103] routinely achieved and on in ten to the sixth [1 in 106] achieved with special techniques). The Flow Cytometry Unit is required in the study and refinement of this technique and its application to diagnosis and measurement of prognostic indicators in different systems. Beckman Coulter is the only source known to NCI that can provide the reagents and instruments that are required to perform the procedures to prepare flow cytometric immunophenotyping. The reagents are proprietary to Beckman Coulter as well as the instruments, they are designed to be compatible with the Flow Cytometer currently located in the laboratory. The Government will be the direct beneficiary of a contract for reagents and supplies because it will maintain and improve the quality of patient care and further cancer research. Changing variables at this time will interrupt correct interpretation of experiments in progress. Period of Performance: Upon award of purchase order through twelve (12) months, with four (4) twelve (12) month option renewals if exercised; FAR Clause 52.217-8 Option to Extend Service (November 1999), FAR Clause 52.217-9 Option to Extend the Term of the Contract (March 2000) applies to this order. The requirement will be a fixed price order. This is not a request for competitive quotations. However, if any interested party believes it can provide the above supplies, it may submit a statement of capabilities. All information furnished shall be in writing and must contain sufficient detail to allow NCI to determine if it can meet the above minimum specifications described herein. Capability statements must be received in the Contracting Office by 1:00 PM EDT (local Washington D.C. time) on September 3, 2002. If you have and questions, please contact Malinda Holdcraft, Purchasing Agent via electronic mail at holdcram@excange.nih.gov or by fax at (301) 402-4513. A determination by the Government not to compete this proposed contract based upon responses to this notice is solely within the discretion of the Government. Information received shall be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted.
- Place of Performance
- Address: NIH/NCI, 9000 Rockville Pike, Bethesda, MD
- Zip Code: 20892
- Country: USA
- Zip Code: 20892
- Record
- SN00143830-W 20020821/020819213232 (fbodaily.com)
- Source
-
FedBizOpps.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |